News
Dr. Mickey Mehta warns that bread could be harmful if eaten regularly and advises people to reduce intake. Though ABS is rare, it is often underdiagnosed and may affect people with gut imbalances or ...
The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections (UTIs), the first such drug approved in decades and the first in a new class of medications.
Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.
The drug is effective against UTIs caused by E. coli, klebsiella, Citrobacter freundii, Staphylococcus saprophyticus and Enterococcus faecalis. The most common side effects reported from using the ...
Hosted on MSN20d
FDA Approves Blujepa for Uncomplicated Urinary Tract InfectionsBlujepa, a first-in-class oral antibiotic, is approved for treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus ...
coli, Klebsiella pneumoniae, Citrobacter freundii complex, Enterococcus faecalis, and a type of staph infection known as Staphylococcus saprophyticus. “The approval of Blujepa is a crucial ...
Health and Me on MSN20d
FDA Gives A Green Light To Blujepa For Treating Uncomplicated UTIsFor the longest the only treatment available for an uncomplicated UTI was nitrofurantoin. But now, FDA has approved Blujepa, another drug that can treat it. Read on to know more.
enables temporal control of transposition to bypass population bottlenecks and enable the quantification of gene fitness during in vivo Citrobacter rodentium infection. RNA-guided CRISPR ...
enables temporal control of transposition to bypass population bottlenecks and enable the quantification of gene fitness during in vivo Citrobacter rodentium infection. Antifungal proteins (AFPs ...
Zacks.com on MSN19d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract InfectionThe FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
The approval is indicated for children aged 12 years and above. It is for uUTIs caused by susceptible micro-organisms such as Escherichia coli, Citrobacter freundii complex, Enterococcus faecalis, ...
College of Life Science & Technology, Xinjiang University, Xinjiang 830046, China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results